A mix of immunosuppressive therapies is typically used to prevent a recipient's body from rejecting a transplanted organ. Rejection is one of the most common causes of death in the first year after heart transplantation.
"Until now, there has been a lack of definitive clinical trial data comparing commonly used immunosuppressive agents, and this has caused some debate over what is the most advantageous combination therapies for heart transplant recipients," said Dr. Jon Kobashigawa, lead author of the study and medical director of the UCLA Heart Transplant Program. "We now have results that demonstrate benefits in treating non-cellular and humoral rejection and this is significant step forward for heart transplant patients."
The study results, presented at the 6th American Transplant Congress in Seattle, involved more than 340 heart transplant recipients, and evaluated three combination therapies: 1) TAC + mycophenolate mofetil (MMF) and steroids, 2) cyclosporine microemulsion (CYA) + MMF and steroids, and 3) TAC + sirolimus (SRL) and steroids.
The primary purpose of this study was to compare the incidence of rejection requiring treatment, as measured by the International Society for Heart and Lung Transplantation (ISHLT) grading system.
Humoral rejection has been recently described in liver, kidney and heart transplant recipients by the National Institutes of Health (NIH) Consensus Conference. Humoral rejection is caused by the body making antibodies that can attack the donor organ, which is similar to the way that anti
'"/>
Contact: Amy Waddell
awaddell@mednet.ucla.edu
310-794-8672
University of California - Los Angeles
22-May-2005